ESO-20-0107 Revision 1

Title: Rates, Risks and Routes to Reduce Vascular Dementia (R4VaD), a UK wide multicentre prospective observational cohort study of cognition after stroke: Protocol.

DECLARATIONS

Conflicting interests:

RMT, HE, AP-J, NS, YHM, TR, FD, HSM, None

PB was a co-Chief Investigator of PHADER and reports receiving honoraria from Phagenesis, DiaMedica, Moleac, Nestle, Sanofi

TQ has received investigator initiated funding from BMS and Pfizer for projects on cardiovascular disease and cognition

FD holds an NHS Research Scotland Research Fellowship

DW Honoraria (speaking) from Bayer 2016, 2017, 2018 (talks or debates on intracerebral haemorrhage, atrial fibrillation, dementia); Honoraria (chairing) from Portola and Bayer (2019); Consultancy fees from Bayer (2017; embolic stroke of undetermined source), Alnylam (2019; cerebral amyloid angiopathy), Portola (2019, 2020; andexanet alpha)

RM has received BP monitoring equipment for research from Omron and is working with them to develop a telemonitoring system. All fees for this work are paid to his institution.

Funding:

R4VaD is funded by the UK Stroke Association, British Heart Foundation and Alzheimer's Society Priority Programme Award in Vascular Dementia (16 VAD 07), and the UK MRC Dementia Platform UK. The work is also supported by the UK MRC Dementia Research Institute. PB is Stroke Association Professor of Stroke Medicine; PB and TGR are National Institute for Health Research (NIHR) Senior Investigators. FD is funded by a Stroke Association-Garfield Weston Foundation Senior Clinical Lectureship (TSA LECT 2015/04) and an NHS Research Scotland Research Fellowship. TQ is funded by a Stroke Association/Chief Scientist Office Scotland Senior Clinical Lectureship for studies in post stroke cognitive decline. RT is funded through a British Heart Foundation Chair Award (CH/12/4/29762). HE is funded by Lancashire Teaching Hospitals NHS Foundation Trust and Lancaster University. APJ is funded by a Stroke Association Margaret Giffen Reader Award (SA L-RC 19\100000). HSM is supported by infrastructure support from the Cambridge University Hospitals NIHR Comprehensive Biomedical Research Centre.

The views expressed by the authors are not necessarily those of the NIHR or the Department of Health and Social Care.

Informed consent:

All participants, or their appropriate guardian, and informants, give written informed consent.

Ethical approval:

R4VaD is approved by Ethics Committees in Scotland (A Research Ethics Committee; Ref 18/SS/055), England (Health Research Authority), Wales (Health and Care Research) and Northern Ireland (all Northeast Newcastle and North Tyneside 1; Ref 18/NE/0150). NHS Research and Innovation Office approval is given in each participating site.
R4VaD is registered (ISRCTN18274006).

Contributorship:

RB, JMW, FD drafting paper

PB, TQ, EB, TR, RMT, DJW, RJM, HE, APJ, HSM, critical comment,

TQ, PB, FD, DJW, HSM, JTO'B, planning and choice of assessments

JMW, PB, TQ, FD, design of CRF

JMW, RB, FD, ethics and regulatory approvals

Guarantor:

JM Wardlaw

Acknowledgements

We thank the NIHR Clinical Research Network's Stroke and Dementia and Neurodegenerative Diseases teams for help with recruitment.